Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial, European Journal of Cancer, vol.78, pp.61-70, 2017. ,
DOI : 10.1016/j.ejca.2017.03.007
Exposure???response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial, Cancer Chemotherapy and Pharmacology, vol.16, issue.5, 2017. ,
DOI : 10.1208/s12248-014-9631-6
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients, Clinical Pharmacokinetics, vol.108, issue.5, pp.1381-94, 2016. ,
DOI : 10.1038/bjc.2013.79
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients, Clinical Cancer Research, vol.17, issue.19, pp.6329-6366, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-1081
URL : https://hal.archives-ouvertes.fr/hal-00616314
Target-mediated drug disposition model for drugs that bind to more than one target, Journal of Pharmacokinetics and Pharmacodynamics, vol.63, issue.5, pp.323-369, 2010. ,
DOI : 10.1007/BF00199290
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer, International Journal of Colorectal Disease, vol.16, issue.2, pp.96-101, 2001. ,
DOI : 10.1007/s003840000266
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, British Journal of Cancer, vol.53, issue.7, pp.978-85, 2007. ,
DOI : 10.1016/j.canlet.2003.09.018
Correlation Between Tumor Growth Delay and Expression of Cancer and Host VEGF, VEGFR2, and Osteopontin in Response to Radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.72, issue.3, pp.918-944, 2008. ,
DOI : 10.1016/j.ijrobp.2008.06.1925
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer, The Journal of Experimental Medicine, vol.2008, issue.13, pp.2855-68, 2010. ,
DOI : 10.3748/wjg.14.2662